Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bhavnani, S.
Right arrow Articles by Schentag, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bhavnani, S.
Right arrow Articles by Schentag, J.
American Journal of Health-System Pharmacy, Vol 60, Issue 19, 1962-1970
Copyright © 2003 by American Society of Health-System Pharmacists

Articles

Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals

SM Bhavnani, WA Callen, A Forrest, KK Gilliland, DA Collins, JA Paladino, and JJ Schentag


The effect of fluoroquinolone use on the susceptibility of Pseudomonas aeruginosa to fluoroquinolones in U.S. hospitals was studied. Benchmarking surveys were sent annually to pharmacists practicing in U.S. hospitals from 1993 to 1999. Data collected included hospital characteristics, antimicrobial expenditures and use, antimicrobial stewardship activities, and bacterial susceptibilities. Antimicrobial expenditures were normalized for the number of occupied beds (OBs) per year. General linear modeling and repeated-measures mixed-effects modeling were used to determine factors predictive of P. aeruginosa susceptibility to fluoroquinolones. A total of 174 hospitals provided data for fluoroquinolone expenditures and susceptibility of P. aeruginosa; the median number of years of data was 3 (range, 1-6), representing 416 hospital years. Community hospitals contributed a majority of the data. Median fluoroquinolone expenditures increased gradually from $230 per OB in 1993 to $400 per OB in 1998. A 55% increase to $620 per OB occurred in 1999, largely because of increased spending on levofloxacin. Susceptibility to ciprofloxacin was commonly used to assess fluoroquinolone susceptibility. The median susceptibility of P. aeruginosa to ciprofloxacin decreased from 84% to 71%. Increasing expenditures for ofloxacin and levofloxacin, but not ciprofloxacin, were associated with decreasing P. aeruginosa susceptibility to ciprofloxacin. In the final multivariable model, each study year after 1993 and every increase in ofloxacin expenditure of $100 per OB were associated with decreases in P. aeruginosa susceptibility. Data from a benchmarking survey of U.S. hospitals for 1993-1999 revealed increases in levofloxacin expenditures, total fluoroquinolone expenditures, expenditures for nonfluoroquinolone antipseudomonal antimicrobials, and total antimicrobial expenditures in 1999. Increases in expenditures for levofloxacin and ofloxacin were associated with a significant decrease in P. aeruginosa susceptibility to ciprofloxacin.
 



This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
J. A. Paladino, J. L. Sunderlin, M. E. Singer, M. H. Adelman, and J. J. Schentag
Influence of extended-spectrum {beta}-lactams on gram-negative bacterial resistance
Am. J. Health Syst. Pharm., June 15, 2008; 65(12): 1154 - 1159.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. A. Paladino, J. L. Sunderlin, M. H. Adelman, M. E. Singer, and J. J. Schentag
Observations on vancomycin use in U.S. hospitals
Am. J. Health Syst. Pharm., August 1, 2007; 64(15): 1633 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
M. E. Falagas, D. K. Matthaiou, and K. Z. Vardakas
Fluoroquinolones vs {beta}-Lactams for Empirical Treatment of Immunocompetent Patients With Skin and Soft Tissue Infections: A Meta-analysis of Randomized Controlled Trials
Mayo Clin. Proc., December 1, 2006; 81(12): 1553 - 1566.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. A. Bosso and P. D. Mauldin
Using Interrupted Time Series Analysis To Assess Associations of Fluoroquinolone Formulary Changes with Susceptibility of Gram-Negative Pathogens and Isolation Rates of Methicillin-Resistant Staphylococcus aureus.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2106 - 2112.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. S. Kaye, Z. A. Kanafani, A. E. Dodds, J. J. Engemann, S. G. Weber, and Y. Carmeli
Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa.
Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2192 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. P. Hammel, S. M. Bhavnani, R. N. Jones, A. Forrest, and P. G. Ambrose
Comparison of Censored Regression and Standard Regression Analyses for Modeling Relationships between Antimicrobial Susceptibility and Patient- and Institution-Specific Variables
Antimicrob. Agents Chemother., January 1, 2006; 50(1): 62 - 67.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Kriengkauykiat, E. Porter, O. Lomovskaya, and A. Wong-Beringer
Use of an Efflux Pump Inhibitor To Determine the Prevalence of Efflux Pump-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa
Antimicrob. Agents Chemother., February 1, 2005; 49(2): 565 - 570.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Society of Health-System Pharmacists.